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I N T R O D U C T I O N
In Cushing’s syndrome, there is an excess of cortisol secre-
tion due to hyperfunction of the adrenal cortex. Hypersecre-
tion of cortisol may be ACTH dependent or independent.
The latter is present in an adrenal adenoma/carcinoma
or bilateral macronodular adrenal hyperplasia. In some of
these patients cortisol secretion is driven by stimuli other
than ACTH, such as gastric inhibitory polypeptide (GIP),
vasopressin, catecholamines or luteinising hormone (LH).1
LH-responsive Cushing’s syndrome was first described by
Lacroix et al.2 In their patient in vivo investigations demon-
strated that cortisol secretion was LH driven, but in vitro
investigations were not performed.
Recently, in vitro studies in two patients with LH-responsive
Cushing’s syndrome demonstrated LH receptor mRNA in
hyperplastic adrenal cells.3 Definitive proof that cortisol
secretion was LH dependent could not be provided, because
both patients refused LH-suppressive therapy. We now
report another patient with LH-responsive Cushing’s syn-
drome. Our patient responded to GnRH agonist therapy
with a profound decrease in 24-hour urinary cortisol
excretion, which proves that in this patient cortisol secretion
was indeed LH driven. In vitro studies demonstrated LH
receptor mRNA expression in the adrenal cells.
C A S E  R E P O R T
A 48-year-old woman presented with an 18-month history
of fatigue, weight gain of 15 kg, muscular weakness and
emotional instability. She reported an absence of menses for
2.5 years. She had had four uncomplicated pregnancies
with no signs of transient Cushing’s syndrome and no
abnormal weight gain. She was not taking any medication.
Physical examination revealed a woman with classical
clinical features of Cushing’s syndrome (hypertension,
moonface, buffalo hump, truncal obesity, atrophy of the
skin and easy bruising). Endocrine evaluation demonstrated
ACTH-independent hypercortisolism. A computed tomo-
graphy showed bilateral macronodular adrenal hyperplasia.
In vivo stimulation tests (table 1) showed increases in cor-
tisol production after administration of GnRH (Etipharma,
Assen, the Netherlands, 100 g iv), recombinant human
LH (rhLH, Serono, Rome, Italy, 300 IU im), and cisapride
(Janssen-Cilag, Tilburg, the Netherlands, 10 mg orally).
No cortisol response was seen after administration of
recombinant human FSH (rhFSH, Organon, Oss, the
Netherlands, 300 IU im) and there were no abnormal
cortisol responses to meals.
LH-responsive Cushing’s syndrome associated with bilateral
macronodular adrenal hyperplasia was diagnosed and treat-
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Table 1
In vivo cortisol responses to GnRH, rhLH, cisapride and
rhFSH (plasma cortisol values are expressed as mol/l)
BASELINE VALUE PEAK VALUE
GnRH (100 g iv) 0.54 0.77
RhLH (300 IU im) 0.23 1.30
Cisapride (10 mg po) 0.57 2.90
RhFSH (300 IU im) 0.48 0.55
ment was started with the GnRH agonist leuprolide acetate,
3.6 mg sc every four weeks. Serum LH levels declined
rapidly from high postmenopausal values to lower than the
detection limit of the assay after two months. This was
accompanied with a decline in 24-hour urinary cortisol
excretion, which became normal six months after starting
treatment with leuprolide acetate (figure 1). However, the
complaints and symptoms of Cushing’s syndrome only
partially disappeared and 24-hour urinary cortisol excretion
was again above normal eight months after starting leupro-
lide acetate. Subsequently the patient underwent a laparo-
scopic bilateral adrenalectomy. Histological examination
of the removed adrenal glands revealed macronodular
adrenocortical hyperplasia. The size of the adrenals was
6 cm (right side) and 9 cm (left side).
The results of the in vitro studies showed a significant
increase in cortisol production after administration of
ACTH1-24 and metoclopramide (table 2). Remarkably,
the response of cortisol to LH was absent in vitro.
LH receptor mRNA expression was demonstrated in
adrenal tissue although in low concentration (ratio of LH
receptor mRNA to -actin mRNA was 0.68; this ratio was
0.58 and 1.07 in two control patients, respectively).
D I S C U S S I O N
In patients with ACTH-independent Cushing’s syndrome
due to an adrenal adenoma/carcinoma or bilateral macro-
nodular adrenal hyperplasia, cortisol secretion can be stimu-
lated by hormones other than ACTH due to aberrant expres-
sion of one or more G-protein-coupled receptors.1 Until
now such aberrant stimulation of cortisol has been demon-
strated for GIP, vasopressin, 5 hydroxytryptamine (5HT7
receptor), -adrenergic receptor agonists and angiotensin II.
Increased expression of eutopic receptors can also cause
cortisol hypersecretion; this mechanism explains the
stimulation of cortisol secretion in patients with ACTH-
independent Cushing’s syndrome by vasopressin, LH/
human chorionic gonadotropin (HCG), 5 hydroxytryptamine
(5HT4 receptor) and leptin.1
In our patient with LH-dependent Cushing’s syndrome
we demonstrated, in line with the data of Lacroix et al.,2 that
suppression of enhanced LH levels in vivo by leuprolide
acetate led to suppression of cortisol levels. We can not
explain the unexpected absence of a response of cortisol to
LH in vitro. We hypothesise that stimulation of LH recep-
tors needs, besides LH, a cofactor that is lacking in vitro.
Furthermore, in our patient adrenalectomy was performed
Bovenberg, et al. Leuprolide acetate therapy in Cushing’s syndrome.
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Figure 1
Urinary cortisol excretion ( ) and serum LH levels
( ) before and during treatment with leuprolide acetate
(3.6 mg sc every 4 weeks)
The first injection was given on 14 January 1999 (arrow) and the last
one on 4 November 1999. Bilateral adrenalectomy was performed on
26 November 1999 (dashed arrow). The horizontal dashed line 
represents the upper limit of normal for 24-hour urinary cortisol
excretion.
Table 2
In vitro cortisol responses of cultured adrenal adenoma cells
to GnRH, rhLH, rhFSH, ACTH1-24 and metoclopramide
(two-hour stimulated cortisol values, expressed as the per-
centage of control, untreated cells)
TEST SUBSTANCE CORTISOL VALUE (% CONTROL)
Control 100 ± 8
GnRH 10 nM 92 ± 7
100 nM 96 ± 1
RhLH 10 mIU/ml 99 ± 7
50 mIU/ml 100 ± 10
100 mIU/ml 95 ± 3
1000 mIU/ml 100 ± 16
RhFSH 10 mIU/ml 87 ± 2
50 mIU/ml 92 ± 10
100 mIU/ml 90 ± 11
1000 mIU/ml 101 ± 6
ACTH1-24 16 pg/ml 227 ± 4°
32 pg/ml 267 ± 31°
64 pg/ml 275 ± 32°
128 pg/ml 310 ± 42°
615 pg/ml 400 ± 30°
Metoclopramide 0.1 M 184 ± 20a
1 M 372 ± 24°
10 M 454 ± 8°
Data are expressed as mean ( n = 3) ± SD; ap<0.01 vs control, °p<0.001 vs
control. For methods see Feelders et al.3
after seven months of treatment with leuprolide acetate,
which may have influenced the in vitro results, if suppres-
sion of LH levels causes downregulation of LH receptor
expression. In our patient in vitro investigations demon-
strated a cortisol response to ACTH and metoclopramide
(that exerts its action via the 5HT4 receptor), in line with
the results of Feelders et al.3
Only very few patients with LH-responsive Cushing’s
syndrome and ACTH-independent macronodular adrenal
hyperplasia have been described so far. In the first patient,
described by Lacroix et al.,2 administration of the long-acting
gonadotropin-releasing hormone (GnRH) analogue leupro-
lide acetate led to suppression of endogenous LH and nor-
malisation of cortisol production. In this patient cisapride
and metoclopramide also stimulated plasma cortisol.
Feelders et al.3 described two women with LH-responsive
Cushing’s syndrome and ACTH-independent macro-
nodular adrenal hyperplasia. Both patients had aberrant
responses to GnRH, LH, hCG, cisapride and metoclo-
pramide. mRNA encoding the LH receptor was slightly
higher in the macronodular adrenals from these patients
than in normal adrenals.
In our patient with ACTH-independent macronodular
adrenal hyperplasia and Cushing’s syndrome with aberrant
responses to GnRH, LH and cisapride in vivo and to meto-
clopramide in vitro suppression of endogenous LH with
leuprolide acetate only partially improved hypercortisolism.
This may be due to persistent aberrant stimulation of
cortisol secretion via 5HT4 receptors, but may also indicate
the presence of either other, unidentified, aberrant receptors
or another mechanism that regulates cortisol secretion.
Many questions with respect to Cushing’s syndrome
variants secondary to aberrant hormone receptors remain
unanswered. Nevertheless, the phenomenon of cortisol
stimulation via receptors other than the ACTH receptor
opens new possibilities to treatment of ACTH-independent
Cushing’s syndrome.
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